-+ 0.00%
-+ 0.00%
-+ 0.00%

Genprex says Reqorsa gene therapy data support potential ALK+ NSCLC clinical trial

PUBT·04/20/2026 11:01:35
Listen to the news
Genprex says Reqorsa gene therapy data support potential ALK+ NSCLC clinical trial
  • Genprex reported positive preclinical results for Reqorsa gene therapy in lung cancer studies presented at 2026 AACR Annual Meeting.
  • Data indicated Reqorsa reduced tumor growth in ALK-positive non-small cell lung cancer models, including settings with resistance to existing ALK inhibitors.
  • Separate findings pointed to TROP2 and PTEN as potential biomarkers to identify patients less likely to respond, supporting a more targeted clinical development strategy.
  • Additional preclinical work showed Reqorsa boosted natural killer cell anti-tumor activity, with tumor suppression observed in animal models.
  • Genprex highlighted these results as support for moving toward a future clinical trial, including a potential program in ALK-positive disease.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Genprex Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202604200700PR_NEWS_USPR_____DA37592) on April 20, 2026, and is solely responsible for the information contained therein.